Published in Nat Rev Cardiol on July 21, 2009
Quantitative N-linked glycoproteomics of myocardial ischemia and reperfusion injury reveals early remodeling in the extracellular environment. Mol Cell Proteomics (2011) 1.09
Imaging of the unstable plaque: how far have we got? Eur Heart J (2009) 1.06
Radiolabelled probes for imaging of atherosclerotic plaques. Am J Nucl Med Mol Imaging (2012) 0.93
Receptor-targeted iron oxide nanoparticles for molecular MR imaging of inflamed atherosclerotic plaques. Biomaterials (2011) 0.89
(64)Cu-labeled LyP-1-dendrimer for PET-CT imaging of atherosclerotic plaque. Bioconjug Chem (2014) 0.82
Principles and basic concepts of molecular imaging. Pediatr Radiol (2010) 0.79
In vitro uptake of apoptotic body mimicking phosphatidylserine-quantum dot micelles by monocytic cell line. Nanoscale Res Lett (2014) 0.78
Multimodality PET/MRI agents targeted to activated macrophages. J Biol Inorg Chem (2013) 0.78
A peptide probe for the detection of neurokinin-1 receptor by disaggregation enhanced fluorescence and magnetic resonance signals. Sci Rep (2014) 0.77
By-passing large screening experiments using sequencing as a tool to identify scFv fragments targeting atherosclerotic lesions in a novel in vivo phage display selection. Int J Mol Sci (2012) 0.75
Pet Imaging and its Application in Cardiovascular Diseases. Methodist Debakey Cardiovasc J (2017) 0.75
Inflammation in atherosclerosis. Nature (2002) 28.92
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med (2008) 14.47
Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation (2007) 11.95
The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med (2007) 11.51
Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood (1994) 9.10
Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med (2003) 9.09
In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol (1999) 8.46
Safe handling of nanotechnology. Nature (2006) 7.25
Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat Biotechnol (2005) 5.19
A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest (2001) 4.98
In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol (2006) 3.91
Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation (2007) 3.85
Visualisation of cell death in vivo in patients with acute myocardial infarction. Lancet (2000) 3.71
The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res (2008) 3.71
Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation (2003) 3.58
Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation (2006) 3.57
Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology (1990) 3.50
Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol (2006) 3.43
Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol (2005) 3.34
Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med (2008) 3.33
Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest (1998) 3.17
Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation (2001) 3.12
Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc Natl Acad Sci U S A (2007) 2.99
Nanocrystal core high-density lipoproteins: a multimodality contrast agent platform. Nano Lett (2008) 2.98
Identifying the proteins to which small-molecule probes and drugs bind in cells. Proc Natl Acad Sci U S A (2009) 2.94
Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol (2005) 2.74
Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol (2001) 2.63
In vivo imaging of proteolytic activity in atherosclerosis. Circulation (2002) 2.62
Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation (2008) 2.62
Inflammation in atherosclerosis: visualizing matrix metalloproteinase action in macrophages in vivo. Circulation (2006) 2.56
Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation (2001) 2.55
Real-time catheter molecular sensing of inflammation in proteolytically active atherosclerosis. Circulation (2008) 2.52
Near-infrared fluorescent imaging of matrix metalloproteinase activity after myocardial infarction. Circulation (2005) 2.45
Molecular imaging of inflammation in atherosclerosis with targeted ultrasound detection of vascular cell adhesion molecule-1. Circulation (2007) 2.40
In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci U S A (1998) 2.39
Annexin-V imaging for noninvasive detection of cardiac allograft rejection. Nat Med (2001) 2.26
Optical visualization of cathepsin K activity in atherosclerosis with a novel, protease-activatable fluorescence sensor. Circulation (2007) 2.20
Perturbational profiling of nanomaterial biologic activity. Proc Natl Acad Sci U S A (2008) 2.04
EP-2104R: a fibrin-specific gadolinium-Based MRI contrast agent for detection of thrombus. J Am Chem Soc (2008) 1.98
Activatable magnetic resonance imaging agent reports myeloperoxidase activity in healing infarcts and noninvasively detects the antiinflammatory effects of atorvastatin on ischemia-reperfusion injury. Circulation (2008) 1.97
Tracking the inflammatory response in stroke in vivo by sensing the enzyme myeloperoxidase. Proc Natl Acad Sci U S A (2008) 1.91
In vivo magnetic resonance imaging of acute brain inflammation using microparticles of iron oxide. Nat Med (2007) 1.90
Macrophage scavenger receptor class A: A multifunctional receptor in atherosclerosis. Arterioscler Thromb Vasc Biol (2000) 1.89
Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation (2005) 1.82
MRI to detect atherosclerosis with gadolinium-containing immunomicelles targeting the macrophage scavenger receptor. Magn Reson Med (2006) 1.79
Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J Am Chem Soc (2004) 1.77
Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-independent pathway. J Lipid Res (2003) 1.68
Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes. Circulation (2008) 1.68
Prediction of cardiac death in hemodialysis patients by myocardial fatty acid imaging. J Am Coll Cardiol (2008) 1.62
Transglutaminase activity in acute infarcts predicts healing outcome and left ventricular remodelling: implications for FXIII therapy and antithrombin use in myocardial infarction. Eur Heart J (2008) 1.62
Computed tomography and magnetic resonance imaging for noninvasive coronary angiography and plaque imaging: current and potential future concepts. Circulation (2002) 1.60
High-resolution MRI characterization of human thrombus using a novel fibrin-targeted paramagnetic nanoparticle contrast agent. Magn Reson Med (2000) 1.60
Scintigraphic imaging of matrix metalloproteinase activity in the arterial wall in vivo. Circulation (2004) 1.57
Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma. Clin Cancer Res (2008) 1.54
Molecular imaging of factor XIIIa activity in thrombosis using a novel, near-infrared fluorescent contrast agent that covalently links to thrombi. Circulation (2004) 1.53
Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res (2003) 1.52
Evaluation of matrix metalloproteinases in atherosclerosis using a novel noninvasive imaging approach. Arterioscler Thromb Vasc Biol (2008) 1.41
In vivo uptake of radiolabeled MDA2, an oxidation-specific monoclonal antibody, provides an accurate measure of atherosclerotic lesions rich in oxidized LDL and is highly sensitive to their regression. Arterioscler Thromb Vasc Biol (2000) 1.36
DTPA-bisamide-based MR sensor agents for peroxidase imaging. Org Lett (2005) 1.35
Noninvasive detection of plaque instability with use of radiolabeled annexin A5 in patients with carotid-artery atherosclerosis. N Engl J Med (2004) 1.34
Metabolic imaging with beta-methyl-p-[(123)I]-iodophenyl-pentadecanoic acid identifies ischemic memory after demand ischemia. Circulation (2005) 1.34
An ApoA-I mimetic peptide high-density-lipoprotein-based MRI contrast agent for atherosclerotic plaque composition detection. Small (2008) 1.34
MR imaging of thrombi using EP-2104R, a fibrin-specific contrast agent: initial results in patients. Eur Radiol (2008) 1.32
Chronic thrombus detection with in vivo magnetic resonance imaging and a fibrin-targeted contrast agent. Circulation (2005) 1.31
Behavior of endogenous tumor-associated macrophages assessed in vivo using a functionalized nanoparticle. Neoplasia (2009) 1.28
Extracellular proteases in atherosclerosis and restenosis. Arterioscler Thromb Vasc Biol (2005) 1.27
Molecular imaging of macrophages in atherosclerotic plaques using bimodal PEG-micelles. Magn Reson Med (2007) 1.25
Molecular magnetic resonance imaging of coronary thrombosis and pulmonary emboli with a novel fibrin-targeted contrast agent. Circulation (2005) 1.23
The role of molecular imaging in drug discovery and development. Clin Pharmacol Ther (2008) 1.15
Novel factor XIII probes for blood coagulation imaging. Chembiochem (2003) 1.13
Overview of early response assessment in lymphoma with FDG-PET. Cancer Imaging (2007) 1.12
Vascular biomarkers and surrogates in cardiovascular disease. Circulation (2006) 1.09
Noninvasive detection of programmed cell loss with 99mTc-labeled annexin A5 in heart failure. J Nucl Med (2007) 1.08
Fibrin-targeted perfluorocarbon nanoparticles for targeted thrombolysis. Nanomedicine (Lond) (2007) 1.08
Myeloperoxidase and plaque vulnerability. Arterioscler Thromb Vasc Biol (2004) 1.03
A fluorescent probe for the detection of myeloperoxidase activity in atherosclerosis-associated macrophages. Chem Biol (2007) 0.99
Targeted imaging of myocardial damage. Nat Clin Pract Cardiovasc Med (2008) 0.97
Imaging myocardial metabolism and ischemic memory. Nat Clin Pract Cardiovasc Med (2008) 0.94
Technology insight: targeting of biological molecules for evaluation of high-risk atherosclerotic plaques with magnetic resonance imaging. Nat Clin Pract Cardiovasc Med (2004) 0.93
Annexin A5: an imaging biomarker of cardiovascular risk. Basic Res Cardiol (2008) 0.92
Unbiased discovery of in vivo imaging probes through in vitro profiling of nanoparticle libraries. Integr Biol (Camb) (2009) 0.91
The significance of cardiac sympathetic nervous system abnormality in the long-term prognosis of patients with a history of ventricular tachyarrhythmia. J Nucl Med (2008) 0.84
A 18F-radiolabeled analogue of CGS 27023A as a potential agent for assessment of matrix-metalloproteinase activity in vivo. Q J Nucl Med Mol Imaging (2007) 0.82
Fatty acid metabolism and myocardial perfusion imaging for the evaluation of global left ventricular dysfunction following acute myocardial infarction: comparisons with echocardiography. Int J Cardiol (2009) 0.76